

Marco Canepa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1946952/publications.pdf>

Version: 2024-02-01

92
papers

2,585
citations

201674

27
h-index

214800

47
g-index

93
all docs

93
docs citations

93
times ranked

4421
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical application of CMR in cardiomyopathies: evolving concepts and techniques. <i>Heart Failure Reviews</i> , 2023, 28, 77-95.	3.9	19
2	Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 56-64.	3.0	17
3	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization â€” the first insight from the AC-TIVE Study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e173-e177.	1.8	21
4	Usefulness of the MAGGIC Score in Predicting the Competing Risk of Non-Sudden Death in Heart Failure Patients Receiving an Implantable Cardioverter-Defibrillator: A Sub-Analysis of the OBSERVO-ICD Registry. <i>Journal of Clinical Medicine</i> , 2022, 11, 121.	2.4	2
5	Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	11
6	Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 768-776.	3.0	8
7	Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the <sc>AC-TIVE</sc> study, an <sc>Italian nationwide survey</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 1377-1386.	7.1	43
8	Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2022, 24, 1227-1236.	7.1	28
9	Frequency, characteristics and prognostic impact of hospital readmissions in elderly patients with heart failure: A population study from 2013 to 2017 in Liguria, Northern Italy. <i>International Journal of Cardiology</i> , 2022, 363, 111-118.	1.7	7
10	Acknowledging the complex puzzle that links heart failure hospitalizations to outcomes. Letter regarding the article â€”Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohortâ€™. <i>European Journal of Heart Failure</i> , 2021, 23, 683-683.	7.1	1
11	Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 86-93.	3.0	34
12	Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 12-18.	3.0	38
13	Tailoring risk prediction at the patient level: future perspectives in cardiovascular medicine. <i>International Journal of Cardiology</i> , 2021, 322, 51-52.	1.7	0
14	The impossible quest to make cardiac amyloidosis diagnosis easy. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13512.	3.4	2
15	Chronic obstructive pulmonary disease and comorbidities in heart failure: the next frontier of sodium-glucose co-transporter 2 inhibitors?. <i>European Journal of Heart Failure</i> , 2021, 23, 644-647.	7.1	3
16	Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: The ACTUAL study. <i>International Journal of Cardiology</i> , 2021, 329, 144-147.	1.7	17
17	Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratic principle â€”oedo no harmâ€?. <i>European Journal of Heart Failure</i> , 2021, , .	7.1	0
18	Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. <i>ESC Heart Failure</i> , 2021, 8, 3369-3374.	3.1	18

#	ARTICLE	IF	CITATIONS
19	Use of loop diuretics in chronic heart failure: do we adhere to the <sc>Hippocratic</sc> principle "do no harm"? European Journal of Heart Failure, 2021, 23, 1068-1075.	7.1	4
20	Brugada syndrome and syncope: a practical approach for diagnosis and treatment. Europace, 2021, 23, 996-1002.	1.7	29
21	Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Failure, 2021, 8, 3547-3556.	3.1	29
22	Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications. European Journal of Clinical Investigation, 2021, 51, e13665.	3.4	5
23	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry. International Journal of Cardiology, 2021, 343, 63-72.	1.7	23
24	Sport practice in hypertrophic cardiomyopathy: running to stand still?. International Journal of Cardiology, 2021, 345, 77-82.	1.7	12
25	Frequency, predictors and prognostic impact of implantable cardioverter defibrillator shocks in a primary prevention population with heart failure and reduced ejection fraction. Journal of Cardiovascular Medicine, 2021, 22, 118-125.	1.5	1
26	Unmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey. European Heart Journal Supplements, 2021, 23, .	0.1	0
27	Medical treatment with ARNI may reduce indications for primary prevention of sudden cardiac death in heart failure with reduced ejection fraction: insights from discover-ARNI, a multicentre Italian register. European Heart Journal Supplements, 2021, 23, .	0.1	0
28	Prevalence and prognostic significance of RV uptake (biventricular uptake) at planar scintigraphy in patients with ATTR cardiac amyloidosis. European Heart Journal Supplements, 2021, 23, .	0.1	1
29	Efficacy of additional medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis. European Heart Journal Supplements, 2021, 23, .	0.1	0
30	Deformation imaging by strain in chronic heart failure over sacubitril-valsartan: a multicentre echocardiographic registry (discover)ARNI. European Heart Journal Supplements, 2021, 23, .	0.1	0
31	Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1314-1321.	5.3	82
32	Brugada syndrome and syncope: A systematic review. Journal of Cardiovascular Electrophysiology, 2020, 31, 3334-3338.	1.7	23
33	Supremacy of echocardiography in the diagnostic workup of systemic AL amyloidosis. European Heart Journal, 2020, 41, 3487-3487.	2.2	1
34	Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2020, 9, e016309.	3.7	23
35	Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007230.	3.9	48
36	Cancer in chronic heart failure patients in the GISSI-HF trial. European Journal of Clinical Investigation, 2020, 50, e13273.	3.4	8

#	ARTICLE	IF	CITATIONS
37	Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study. <i>Internal and Emergency Medicine</i> , 2020, 15, 1219-1229.	2.0	16
38	Testing longitudinal data for prognostication in ambulatory heart failure patients with reduced ejection fraction. A proof of principle from the GISSI-HF database. <i>International Journal of Cardiology</i> , 2020, 313, 89-96.	1.7	5
39	Real-world versus trial patients with transthyretin amyloid cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 1479-1481.	7.1	17
40	Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. <i>JACC: Heart Failure</i> , 2019, 7, 823-833.	4.1	55
41	Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure. <i>Internal and Emergency Medicine</i> , 2019, 14, 1083-1090.	2.0	5
42	Modes of death and prognostic outliers in chronic heart failure. <i>American Heart Journal</i> , 2019, 208, 100-109.	2.7	7
43	Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation. <i>Journal of Cardiovascular Translational Research</i> , 2019, 12, 514-516.	2.4	3
44	Letter regarding the article "Heart failure with preserved ejection fraction: from mechanisms to therapies" by Lam and colleagues. <i>European Heart Journal</i> , 2019, 40, 703-704.	2.2	3
45	Time for an "Atrial-Watchful" Approach for Heart Failure Patients With a Cardiac Implantable Electronic Device. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1187-1188.	2.8	1
46	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. <i>European Journal of Heart Failure</i> , 2018, 20, 879-887.	7.1	138
47	Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	47
48	Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia. <i>International Journal of Cardiology</i> , 2018, 255, 215-220.	1.7	6
49	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. <i>Oncologist</i> , 2018, 23, 936-942.	3.7	69
50	E/e ² ratio and outcome prediction in hypertrophic cardiomyopathy: the influence of outflow tract obstruction. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 101-107.	1.2	22
51	Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 100-110.	7.1	86
52	Long-Term Left Ventricular Remodeling of Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018, 122, 1924-1931.	1.6	15
53	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. <i>JACC: Heart Failure</i> , 2018, 6, 452-462.	4.1	94
54	Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects. <i>International Journal of Cardiology</i> , 2018, 271, 219-227.	1.7	19

#	ARTICLE	IF	CITATIONS
55	Data regarding the effects of thrombin and dabigatran-inhibited thrombin on protease-activated receptor 1 and activation of human atrial fibroblasts. Data in Brief, 2018, 19, 925-931.	1.0	2
56	Linking Heart Failure to Cancer. Circulation, 2018, 138, 735-742.	1.6	115
57	Metabolic and densitometric correlation between atherosclerotic plaque and trabecular bone: an F-Natrium-Fluoride PET/CT study. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 387-396.	1.0	2
58	Sometimes they come back. Journal of Cardiovascular Medicine, 2017, 18, 443-446.	1.5	2
59	5-Fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. British Journal of Pharmacology, 2017, 174, 3713-3726.	5.4	37
60	Methods, accuracy and clinical implications of atrial fibrillation detection by cardiac implantable electronic devices. International Journal of Cardiology, 2017, 236, 262-269.	1.7	9
61	T1 mapping with cardiovascular magnetic resonance: an emerging clinical biomarker. Heart, 2017, 103, 326.1-326.	2.9	1
62	Longitudinal Association Between Serum Uric Acid and Arterial Stiffness. Hypertension, 2017, 69, 228-235.	2.7	59
63	Lower Mitochondrial Energy Production of the Thigh Muscles in Patients With Low-Normal Ankle-Brachial Index. Journal of the American Heart Association, 2017, 6, .	3.7	23
64	Impact of peak provoked left ventricular outflow tract gradients on clinical outcomes in hypertrophic cardiomyopathy. International Journal of Cardiology, 2017, 243, 290-295.	1.7	17
65	What can we learn from pulmonary function testing in heart failure?. European Journal of Heart Failure, 2017, 19, 1222-1229.	7.1	46
66	Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. Cardiology, 2017, 136, 128-137.	1.4	46
67	Diagnostic value of ischemia severity at myocardial perfusion imaging in elderly persons with suspected coronary disease. Journal of Cardiovascular Medicine, 2016, 17, 719-728.	1.5	4
68	Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly. Heart, 2016, 102, 1087-1094.	2.9	30
69	The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity. Scientific Reports, 2016, 6, 29994.	3.3	52
70	Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure. Heart Failure Reviews, 2016, 21, 539-547.	3.9	27
71	Testosterone Antagonizes Doxorubicin-Induced Senescence of Cardiomyocytes. Journal of the American Heart Association, 2016, 5, .	3.7	62
72	Prevalent cardiac, renal and cardiorenal damage in patients with advanced abdominal aortic aneurysms. Internal and Emergency Medicine, 2016, 11, 205-212.	2.0	10

#	ARTICLE	IF	CITATIONS
73	Correlation between thoracic aorta 18F-sodium fluoride uptake and cardiovascular risk. World Journal of Radiology, 2016, 8, 82.	1.1	15
74	Clinical characteristics and prognostic impact of atrial fibrillation in patients with chronic heart failure. World Journal of Cardiology, 2016, 8, 647.	1.5	7
75	Recurrent and Residual Shunts After Patent Foramen Ovale Closure: Results From a Long-Term Transcranial Doppler Study. Journal of Interventional Cardiology, 2015, 28, 600-608.	1.2	17
76	Doxorubicin Impairs the Insulin-Like Growth Factor-1 System and Causes Insulin-Like Growth Factor-1 Resistance in Cardiomyocytes. PLoS ONE, 2015, 10, e0124643.	2.5	16
77	From Arterial Stiffness to Heart Failure: Still a Long Way to Go. Journal of the American Heart Association, 2015, 4, .	3.7	6
78	Comparison of Outcomes in Patients With Nonobstructive, Labile-Obstructive, and Chronically Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2015, 116, 938-944.	1.6	29
79	Indoxyl Sulfate: A Candidate Target for the Prevention and Treatment of Cardiovascular Disease in Chronic Kidney Disease. Current Drug Targets, 2015, 16, 366-372.	2.1	22
80	Impact of Central Obesity on the Estimation of Carotid-Femoral Pulse Wave Velocity. American Journal of Hypertension, 2014, 27, 1209-1217.	2.0	34
81	Vitamin D modulates the association of circulating insulin-like growth factor-1 with carotid artery intima-media thickness. Atherosclerosis, 2014, 236, 418-425.	0.8	17
82	Using unsupervised learning to determine risk level for left ventricular diastolic dysfunction. , 2014, , .		1
83	Role of bone mineral density in the inverse relationship between body size and aortic calcification: Results from the Baltimore Longitudinal Study of Aging. Atherosclerosis, 2014, 235, 169-175.	0.8	15
84	The association between leptin and depressive symptoms is modulated by abdominal adiposity. Psychoneuroendocrinology, 2014, 42, 1-10.	2.7	39
85	Prevalence, Clinical Correlates, and Functional Impact of Subaortic Ventricular Septal Bulge (from) Tj ETQq1 1 0.784314 rgBT/Overlo	1.6	23
86	Pulse Wave Velocity Testing in the Baltimore Longitudinal Study of Aging. Journal of Visualized Experiments, 2014, , e50817.	0.3	8
87	Longitudinal Trajectories of Arterial Stiffness and the Role of Blood Pressure. Hypertension, 2013, 62, 934-941.	2.7	333
88	Relationship Between Inter-Arm Difference in Systolic Blood Pressure and Arterial Stiffness in Community-Dwelling Older Adults. Journal of Clinical Hypertension, 2013, 15, 880-887.	2.0	59
89	Comparison of Clinical Presentation, Left Ventricular Morphology, Hemodynamics, and Exercise Tolerance in Obese Versus Nonobese Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2013, 112, 1182-1189.	1.6	42
90	Arterial Stiffness and Vitamin D Levels: the Baltimore Longitudinal Study of Aging. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3717-3723.	3.6	80

#	ARTICLE	IF	CITATIONS
91	Contribution of Central Adiposity to Left Ventricular Diastolic Function (from the Baltimore) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj 9	2.6	41
92	p38 MAPK and JNK Antagonistically Control Senescence and Cytoplasmic p16INK4A Expression in Doxorubicin-Treated Endothelial Progenitor Cells. PLoS ONE, 2010, 5, e15583.	2.5	70